Paresh N. Soni

发表

Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters

R. Braeckman, W. Stirtan, Paresh N. Soni, 2014, Clinical Drug Investigation.

Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.

T. A. Jacobson, S. Glickstein, Paresh N. Soni, 2012, Journal of clinical lipidology.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

H. Bays, M. Manku, R. Braeckman, 2013, Prostaglandins, leukotrienes, and essential fatty acids.

The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials

Chunming Li, Paresh N. Soni, G. Cawkwell, 2009, Current medical research and opinion.

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Deepak L. Bhatt, S. Murphy, J. Tardif, 2017, Clinical cardiology.

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.

C. Ballantyne, H. Bays, R. Juliano, 2015, Metabolic syndrome and related disorders.

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

C. Ballantyne, H. Bays, R. Braeckman, 2013, American Journal of Cardiovascular Drugs.

United States Patent ( 10 ) Patent No . : US 8 , 324 , 195 B 2

R. Braeckman, Paresh N. Soni, Horrobin Richboro, 2017 .

Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects

R. Braeckman, W. Stirtan, Paresh N. Soni, 2013, Clinical pharmacology in drug development.

Authors' reply to commentary entitled “EPA and DHA: Distinct yet essential n-3 fatty acids”

T. A. Jacobson, S. Glickstein, Paresh N. Soni, 2012 .

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

C. Ballantyne, J. Kastelein, E. Stein, 2012, The American journal of cardiology.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

C. Ballantyne, J. Kastelein, H. Bays, 2011, The American journal of cardiology.

Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.

Richard J. Thompson, M. H. Jørgensen, H. Arnell, 2021, Clinics and research in hepatology and gastroenterology.

First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals

Yi Wang, Richard Larouche, Zhao-Xue Yu, 2015 .

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

C. Ballantyne, J. Kastelein, H. Bays, 2013, Cardiovascular Diabetology.

Methods to determine the minimum important difference for a sexual event diary used by postmenopausal women with hypoactive sexual desire disorder.

L. Gunter, D. Patrick, C. Spino, 2007, The journal of sexual medicine.

ORIGINAL RESEARCH—OUTCOMES ASSESSMENT Methods to Determine the Minimum Important Difference for a Sexual Event Diary Used by Postmenopausal Women with Hypoactive Sexual Desire Disorder

L. Gunter, D. Patrick, C. Spino, 2007 .

Icosapent ethyl for the treatment of hypertriglyceridemia

C. Ballantyne, R. Braeckman, Paresh N. Soni, 2013, Expert opinion on pharmacotherapy.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.

C. Ballantyne, H. Bays, R. Juliano, 2016, Atherosclerosis.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.

C. Ballantyne, H. Bays, R. Juliano, 2014, Journal of clinical lipidology.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

C. Ballantyne, J. Kastelein, J. Otvos, 2012, Journal of clinical lipidology.

A methodology study to develop and validate a screener for hypoactive sexual desire disorder in postmenopausal women.

T. Symonds, S. Leiblum, Paresh N. Soni, 2006, The journal of sexual medicine.

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects

R. Braeckman, W. Stirtan, Paresh N. Soni, 2014, Clinical pharmacology in drug development.

Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults

R. Braeckman, W. Stirtan, Paresh N. Soni, 2014, Drugs in R&D.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).

C. Ballantyne, J. Kastelein, J. Otvos, 2015, Journal of clinical lipidology.

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin

R. Braeckman, W. Stirtan, Paresh N. Soni, 2014, Clinical Drug Investigation.

Etiology, screening, and treatment of hepatocellular carcinoma.

S. Khakoo, G. Dusheiko, L. Grellier, 1996, The Medical clinics of North America.

C. Ballantyne, J. Kastelein, H. Bays, 2011, The American journal of cardiology.